Tags

Type your tag names separated by a space and hit enter

Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
J Chemother. 2003 Aug; 15(4):335-41.JC

Abstract

The in vitro activity of telithromycin, a new ketolide, was compared with beta-lactam antimicrobials against pathogens commonly associated with community-acquired respiratory tract infections. These pathogens were collected during 1999-2000 as part of the ongoing PROTEKT surveillance study. Globally, penicillin nonsusceptibility among Streptococcus pneumoniae (n = 3362) was 36.3%, ranging from 21.5% (Australasia) to 68.0% (Far East). Telithromycin showed higher potency (MIC90 0.12 mg/L) than beta-lactams against S. pneumoniae; 99.9% of all and 99.6% of multi-resistant isolates were susceptible to telithromycin. Among Streptococcus pyogenes isolates (n = 1485), 100% were susceptible to beta-lactams, and the telithromycin MIC50 and MIC90 were both 0.015 mg/L. Among Haemophilus influenzae (n = 2948), 16.6% produced beta-lactamase, which reduced the activity of ampicillin, cefaclor and cefprozil. 99.9% of H. influenzae were susceptible to telithromycin and the MIC range for M. catarrhalis was 0.004-0.5 mg/L. The first year results of PROTEKT confirmed high potency for telithromycin against common respiratory tract pathogens, including beta-lactam-resistant strains.

Authors+Show Affiliations

Second Dept of Internal Medicine, Nagasaki University School of Medicine, Sakamoto, Japan. s-kohno@net.nagasaki-u.ac.jpNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12962361

Citation

Kohno, S, et al. "Comparative in Vitro Activity of Telithromycin and Beta-lactam Antimicrobials Against Bacterial Pathogens From Community-acquired Respiratory Tract Infections: Data From the First Year of PROTEKT (1999-2000)." Journal of Chemotherapy (Florence, Italy), vol. 15, no. 4, 2003, pp. 335-41.
Kohno S, Hoban D, Protekt Surveillance Study Group. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000). J Chemother. 2003;15(4):335-41.
Kohno, S., & Hoban, D. (2003). Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000). Journal of Chemotherapy (Florence, Italy), 15(4), 335-41.
Kohno S, Hoban D, Protekt Surveillance Study Group. Comparative in Vitro Activity of Telithromycin and Beta-lactam Antimicrobials Against Bacterial Pathogens From Community-acquired Respiratory Tract Infections: Data From the First Year of PROTEKT (1999-2000). J Chemother. 2003;15(4):335-41. PubMed PMID: 12962361.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000). AU - Kohno,S, AU - Hoban,D, AU - ,, PY - 2003/9/10/pubmed PY - 2004/1/6/medline PY - 2003/9/10/entrez SP - 335 EP - 41 JF - Journal of chemotherapy (Florence, Italy) JO - J Chemother VL - 15 IS - 4 N2 - The in vitro activity of telithromycin, a new ketolide, was compared with beta-lactam antimicrobials against pathogens commonly associated with community-acquired respiratory tract infections. These pathogens were collected during 1999-2000 as part of the ongoing PROTEKT surveillance study. Globally, penicillin nonsusceptibility among Streptococcus pneumoniae (n = 3362) was 36.3%, ranging from 21.5% (Australasia) to 68.0% (Far East). Telithromycin showed higher potency (MIC90 0.12 mg/L) than beta-lactams against S. pneumoniae; 99.9% of all and 99.6% of multi-resistant isolates were susceptible to telithromycin. Among Streptococcus pyogenes isolates (n = 1485), 100% were susceptible to beta-lactams, and the telithromycin MIC50 and MIC90 were both 0.015 mg/L. Among Haemophilus influenzae (n = 2948), 16.6% produced beta-lactamase, which reduced the activity of ampicillin, cefaclor and cefprozil. 99.9% of H. influenzae were susceptible to telithromycin and the MIC range for M. catarrhalis was 0.004-0.5 mg/L. The first year results of PROTEKT confirmed high potency for telithromycin against common respiratory tract pathogens, including beta-lactam-resistant strains. SN - 1120-009X UR - https://www.unboundmedicine.com/medline/citation/12962361/Comparative_in_vitro_activity_of_telithromycin_and_beta_lactam_antimicrobials_against_bacterial_pathogens_from_community_acquired_respiratory_tract_infections:_data_from_the_first_year_of_PROTEKT__1999_2000__ DB - PRIME DP - Unbound Medicine ER -